Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on DPYD and Dihydropyrimidine dehydrogenase, with related work in Lenalidomide, Capecitabine, Toxicity. Notable publications include 'DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis', 'Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and...', and 'Upfront Genotyping of DPYD * 2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis'.
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer
Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis